How to Interpret the CAT Score for COPD
The CAT score should be interpreted using a cutoff of 10 points to separate low symptom burden (CAT <10) from high symptom burden (CAT ≥10), which directly guides COPD treatment decisions in the GOLD ABCD assessment framework. 1
Primary Interpretation Framework
The GOLD guidelines establish CAT as a comprehensive symptom assessment tool that captures the multidimensional impact of COPD beyond just breathlessness 1. Here's how to interpret the scores:
Basic Cutoff Point
- CAT <10: Low symptom burden
- CAT ≥10: High symptom burden
This threshold of 10 is the validated equivalent to the SGRQ score of ≥25 and separates patients who need more intensive symptom management from those with milder symptoms 1.
Impact Categories (for detailed assessment)
While the primary clinical decision uses the cutoff of 10, the CAT can be further stratified:
- Low Impact: CAT <10
- Medium Impact: CAT 10-20
- High Impact: CAT 21-30
- Very High Impact: CAT 31-40
Research demonstrates that patients in higher CAT categories have progressively worse lung function, physical/mental health status, and more severe exacerbations 2.
Clinical Application in GOLD Assessment
The CAT score combines with exacerbation history to assign patients to GOLD groups A-D, which determines pharmacologic treatment intensity:
- Group A: CAT <10 AND 0-1 exacerbations (not requiring hospitalization)
- Group B: CAT ≥10 AND 0-1 exacerbations (not requiring hospitalization)
- Group C: CAT <10 AND ≥2 exacerbations OR ≥1 hospitalization
- Group D: CAT ≥10 AND ≥2 exacerbations OR ≥1 hospitalization
This classification is independent of spirometric severity and drives treatment decisions based on symptom burden and exacerbation risk 1.
Important Clinical Considerations
Minimum Clinically Important Difference
A change of 2 points on the CAT represents the minimum clinically important difference (MCID) 3. This means:
- Improvement of ≥2 points indicates meaningful clinical benefit from interventions
- Worsening of ≥2 points suggests significant deterioration requiring intervention adjustment
Discordance with mMRC
A critical pitfall: CAT ≥10 and mMRC ≥2 are NOT equivalent despite both indicating high symptoms 4, 5. Studies show:
- Agreement between CAT and mMRC ranges from poor to moderate (κ = 0.13-0.77)
- Approximately 13-32% of patients are classified differently depending on which tool is used
- Some patients have mMRC <2 but CAT ≥10, and vice versa 4, 5
Clinical implication: When assigning patients to low symptom groups, evaluate BOTH CAT and mMRC together to avoid misclassifying high-symptom patients 5. A high score on either tool is sufficient to assign to high symptom groups, but both should be low to confidently assign to low symptom groups.
Prognostic Value
Higher CAT scores predict:
In severe COPD specifically, non-respiratory CAT components (limited activities, confidence leaving home, sleeplessness, energy) are particularly associated with exacerbation risk 6.
Practical Algorithm for Clinical Use
- Administer CAT at every clinical encounter
- Apply cutoff of 10 to determine symptom burden
- Combine with exacerbation history to assign GOLD group (A-D)
- Use GOLD group to guide pharmacotherapy intensity
- Monitor changes ≥2 points as clinically significant responses to treatment
- Cross-check with mMRC when considering low symptom classification
- Reassess regularly as CAT scores correlate with longitudinal exacerbation patterns 2
Common Pitfall to Avoid
Do not rely solely on spirometry (FEV1) for treatment decisions. The GOLD framework deliberately separates spirometric grading from clinical assessment because FEV1 lacks precision at the individual patient level for determining therapeutic options 1. Two patients with identical FEV1 values but different CAT scores and exacerbation histories require different treatment approaches.